Crossref
Can subcutaneous treprostinil be an alternative for treating pulmonary hypertension in patients with systemic sclerosis-related interstitial lung disease?
ARP Rheumatology · 2024
DOI: 10.63032/bbmb6759 ↗Kurz gefasst
Fachartikel in der Zeitschrift ARP Rheumatology, 2024. Verfasst von AC Duarte und 4 weiteren Autor:innen. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Duarte, A., Alegria, S., Vinagre, F., Ferreira, F., & Cordeiro, A. (2024). Can subcutaneous treprostinil be an alternative for treating pulmonary hypertension in patients with systemic sclerosis-related interstitial lung disease?. ARP Rheumatology. https://doi.org/10.63032/bbmb6759
Vancouver
Duarte A, Alegria S, Vinagre F, Ferreira F, Cordeiro A. Can subcutaneous treprostinil be an alternative for treating pulmonary hypertension in patients with systemic sclerosis-related interstitial lung disease?. ARP Rheumatology. 2024. doi:10.63032/bbmb6759
BibTeX
@article{Duarte2024,
author = {Duarte, AC and Alegria, S and Vinagre, F and Ferreira, F and Cordeiro, A},
title = {Can subcutaneous treprostinil be an alternative for treating pulmonary hypertension in patients with systemic sclerosis-related interstitial lung disease?},
journal = {ARP Rheumatology},
year = {2024},
doi = {10.63032/bbmb6759}
}
EUVIMED